CATX Stock Forecast & Price Target

Perspective Therapeutics is attractive because its Lead-212 platform combines precise tumor targeting with a differentiated safety profile, including rapid renal clearance, zero serious renal complications, no significant myelosuppression, and no >Gr4 adverse events. Its imaging-led patient selection and frontloaded dosing strategy may maximize early tumor uptake while potentially preserving tolerability, which supports stronger efficacy economics for VMT-α-NET and VMT01 in melanoma. Fundamentally, the bullish case is reinforced by a broad pipeline across high-value indications, a potential $6B addressable market for PSV594, and manufacturing expansion in early '27 and 2H27 that should support phased and future commercial supply.

Perspective Therapeutics is a clinical-stage biopharmaceutical company whose outlook is weighed down by binary clinical risk, since poorer-than-expected readouts for its product candidates could materially impair both market potential and valuation. Its dependence on favorable reimbursement, regulatory adoption, and competition-sensitive commercialization adds further uncertainty, especially because the company still faces the standard manufacturing and financial risks typical of a development-stage biotech. Although it ended 2Q26 with $237M in cash and cash equivalents and a cash runway into late 2027, it also reported a diluted EPS loss of ($0.22), underscoring continuing losses and reliance on successful execution.